Publications
- Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry2020 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University
- Effect of clinical parameters on second- and third-line erlotinib treatment of EGFR wild type patients with advanced NSCLC2019 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University
- Erlotinib in the treatment of advanced squamous cell NSCLC2013 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Follow-up of expensive pneumo-oncological treatment of advanced non-small cell lung cancer in the I. line of the TULUNG register in the Czech Republic2013 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University
- Clinical registry TULUNG2012 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Monitoring of the expensive pneumooncological tratment of the advanced non-small cell lung cancer (NSCLC) in the 1st line in the TULUNG registry in the Czech Republic2012 | Third Faculty of Medicine, First Faculty of Medicine
- Information on clinical registry Tarceva2010 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, First Faculty of Medicine
- Tarceva Clinical Registry2010 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer2023 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
Loading network view...